195 related articles for article (PubMed ID: 19080728)
21. Apolipoprotein A-I Mimetic Peptide D-4F Reduces Cardiac Hypertrophy and Improves Apolipoprotein A-I-Mediated Reverse Cholesterol Transport From Cardiac Tissue in LDL Receptor-null Mice Fed a Western Diet.
Han J; Zhang S; Ye P; Liu YX; Qin YW; Miao DM
J Cardiovasc Pharmacol; 2016 May; 67(5):412-7. PubMed ID: 26828321
[TBL] [Abstract][Full Text] [Related]
22. Apo A-1 mimetic peptides as atheroprotective agents in murine models.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Fogelman AM
Curr Drug Targets; 2008 Mar; 9(3):204-9. PubMed ID: 18336238
[TBL] [Abstract][Full Text] [Related]
23. Reverse D4F, an apolipoprotein-AI mimetic peptide, inhibits atherosclerosis in ApoE-null mice.
Qin S; Kamanna VS; Lai JH; Liu T; Ganji SH; Zhang L; Bachovchin WW; Kashyap ML
J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):334-43. PubMed ID: 22308547
[TBL] [Abstract][Full Text] [Related]
24. Apolipoprotein A-I mimetic peptides.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Yu N; Ansell BJ; Datta G; Garber DW; Fogelman AM
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1325-31. PubMed ID: 15831812
[TBL] [Abstract][Full Text] [Related]
25. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Wagner AC; Hama S; Hough G; Bachini E; Garber DW; Mishra VK; Palgunachari MN; Fogelman AM
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1932-7. PubMed ID: 15961700
[TBL] [Abstract][Full Text] [Related]
26. Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice.
Vaziri ND; Kim HJ; Moradi H; Farmand F; Navab K; Navab M; Hama S; Fogelman AM; Quiroz Y; Rodriguez-Iturbe B
Nephrol Dial Transplant; 2010 Nov; 25(11):3525-34. PubMed ID: 20488818
[TBL] [Abstract][Full Text] [Related]
27. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties.
Wool GD; Reardon CA; Getz GS
J Lipid Res; 2008 Jun; 49(6):1268-83. PubMed ID: 18323574
[TBL] [Abstract][Full Text] [Related]
28. Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma.
Meriwether D; Imaizumi S; Grijalva V; Hough G; Vakili L; Anantharamaiah GM; Farias-Eisner R; Navab M; Fogelman AM; Reddy ST; Shechter I
J Lipid Res; 2011 Oct; 52(10):1795-809. PubMed ID: 21804067
[TBL] [Abstract][Full Text] [Related]
29. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature.
Navab M; Reddy ST; Van Lenten BJ; Buga GM; Hough G; Wagner AC; Fogelman AM
Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2553-60. PubMed ID: 23077141
[TBL] [Abstract][Full Text] [Related]
30. The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage.
White CR; Datta G; Wilson L; Palgunachari MN; Anantharamaiah GM
Chem Phys Lipids; 2019 Mar; 219():28-35. PubMed ID: 30707910
[TBL] [Abstract][Full Text] [Related]
31. Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides.
Yu R; Yekta B; Vakili L; Gharavi N; Navab M; Marelli D; Ardehali A
Curr Atheroscler Rep; 2008 Apr; 10(2):171-6. PubMed ID: 18417073
[TBL] [Abstract][Full Text] [Related]
32. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides.
Anantharamaiah GM; Mishra VK; Garber DW; Datta G; Handattu SP; Palgunachari MN; Chaddha M; Navab M; Reddy ST; Segrest JP; Fogelman AM
J Lipid Res; 2007 Sep; 48(9):1915-23. PubMed ID: 17570869
[TBL] [Abstract][Full Text] [Related]
33. Apolipoprotein A-I mimetics and high-density lipoprotein function.
Gordon SM; Davidson WS
Curr Opin Endocrinol Diabetes Obes; 2012 Apr; 19(2):109-14. PubMed ID: 22278086
[TBL] [Abstract][Full Text] [Related]
34. Systemic inflammation, intestine, and paraoxonase-1.
Vakili L; Navab KD; Shabihkhani M; Pourtabatabaei N; Vazirian S; Barseghian Z; Seyedali S; Hough G
Adv Exp Med Biol; 2014; 824():83-8. PubMed ID: 25038995
[TBL] [Abstract][Full Text] [Related]
35. Biological properties of apolipoprotein a-I mimetic peptides.
Getz GS; Wool GD; Reardon CA
Curr Atheroscler Rep; 2010 Mar; 12(2):96-104. PubMed ID: 20425244
[TBL] [Abstract][Full Text] [Related]
36. A Compendium of the Biological Effects of Apolipoprotein A-I
Parolini C
J Pharmacol Exp Ther; 2020 Jan; 372(1):54-62. PubMed ID: 31649050
[TBL] [Abstract][Full Text] [Related]
37. L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice.
Peterson SJ; Drummond G; Kim DH; Li M; Kruger AL; Ikehara S; Abraham NG
J Lipid Res; 2008 Aug; 49(8):1658-69. PubMed ID: 18426778
[TBL] [Abstract][Full Text] [Related]
38. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet.
Buga GM; Frank JS; Mottino GA; Hakhamian A; Narasimha A; Watson AD; Yekta B; Navab M; Reddy ST; Anantharamaiah GM; Fogelman AM
J Lipid Res; 2008 Jan; 49(1):192-205. PubMed ID: 17925450
[TBL] [Abstract][Full Text] [Related]
39. High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis.
Favari E; Thomas MJ; Sorci-Thomas MG
J Cardiovasc Pharmacol; 2018 Jun; 71(6):325-331. PubMed ID: 29528874
[TBL] [Abstract][Full Text] [Related]
40. Apolipoprotein A-I mimetic peptide inhibits atherosclerosis by altering plasma metabolites in hypercholesterolemia.
Ou ZJ; Li L; Liao XL; Wang YM; Hu XX; Zhang QL; Wang ZP; Yu H; Zhang X; Hu P; Xu YQ; Liang QL; Ou JS; Luo G
Am J Physiol Endocrinol Metab; 2012 Sep; 303(6):E683-94. PubMed ID: 22535745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
